Acquisition enhances innovation offering and expands biotech footprint across Nordic countries

Ofichem, a European contract development and manufacturing organisation (CDMO) specialising in active pharmaceutical ingredients (APIs) and integrated drug development services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden. This move strengthens Ofichem’s capacity to support early-phase, intellectual property-driven drug substance development and expands its non-GMP capabilities in the small-molecule sector.

The Uppsala facility, previously part of Recipharm and known as OT Chemistry, employs around 20 staff. It focuses on small-scale, early-phase development, encompassing traditional small molecules alongside emerging modalities such as antibody-drug conjugates (ADCs), oligonucleotides, and proteolysis-targeting chimeras (PROTACs).

Dr Weite Oldenziel, CEO and owner of Ofichem, said: “This acquisition is a strategic building block in Ofichem’s broader transformation. Our aim is to serve innovative biotech firms with agile early-stage development solutions. This site offers the expertise and technology to support that ambition.”

This acquisition marks an evolution in Ofichem’s focus, broadening from generics and mid-sized pharmaceutical clients towards deeper engagement with biotech innovators.

The Uppsala site will work closely with Ofichem’s gmp manufacturing operations in Ter Apel, Netherlands, facilitating a smooth transition from early research phases to commercial manufacturing. The deal also extends Ofichem’s access to a client portfolio exceeding 40 biotech and mid-sized pharma companies, boosting its presence across Nordic markets.

Alessia Cogotti, managing director at Ofichem, said: “Welcoming the Uppsala team enhances our geographic and technological reach. It strengthens our ability to support clients from initial concept through to implementation.”

Bruce Vielle, CEO of Meribel, added: “We are pleased to have found a partner in Ofichem who shares our values and commitment to customer success. This partnership allows Meribel to focus more on advancing its drug product solutions while ensuring continuity for customers and projects at the Uppsala site. We believe this collaboration will create long-term benefits for all stakeholders.”

The Uppsala operation will be integrated into Ofichem’s matrix organisation, reporting through group-level leadership in operations, quality, r&d, and business development.

Looking forward, Ofichem plans to further develop its early-stage drug substance network and is considering potential expansions involving larger-scale GMP manufacturing sites in Europe and North America.